1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Aduhelm’s Revised Labeling Could Help Payers Navigate Reimbursement

 
• By Jessica Merrill

The US FDA revised labeling to clarify the target population, which could be helpful in reimbursement discussions for the Alzheimer's therapy.

compass
Revised labeling for Aduhelm could help payers and physicians navigate the treatment landscape • Source: Alamy

The US Food and Drug Administration has revised labeling for Biogen, Inc.'s Aduhelm (aducanumab) to better clarify how it should be used in Alzheimer's patients one month after the drug was approved in the US and following some backlash from legislators, physicians and health care spending watch dogs. The new language could help balance potential broad use and a high price tag in payer negotiations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

 
• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.